BioCentury | Jan 13, 2014
Financial News

CorMedix completes private placement of convertible preferred stock and warrants

...and warrants Raised: $2 million Shares: 200,000 Price: $10 Shares outstanding prior: 16.2 million Investors: ND Partners...
BioCentury | Oct 17, 2005
Strategy

Flu vaccine manufacturers

Flu vaccine manufacturers Company Product Description Status Acambis Influenza vaccine (partnered with Flanders InterUniversity) Vaccine protecting against strains A and B; vaccine will contain a cell surface part of the ion channel protein M2, which...
BioCentury | Aug 29, 2005
Strategy

Biovitrum's pipeline

Biovitrum's pipeline Biovitrum's pipeline After lead compounds BVT.933 and BVT.3498 (AMG 331) failed in the clinic in 2003 and 2004, Biovitrum set out to fill its pipeline via acquisitions, and early this year set itself...
Items per page:
1 - 3 of 3
BioCentury | Jan 13, 2014
Financial News

CorMedix completes private placement of convertible preferred stock and warrants

...and warrants Raised: $2 million Shares: 200,000 Price: $10 Shares outstanding prior: 16.2 million Investors: ND Partners...
BioCentury | Oct 17, 2005
Strategy

Flu vaccine manufacturers

Flu vaccine manufacturers Company Product Description Status Acambis Influenza vaccine (partnered with Flanders InterUniversity) Vaccine protecting against strains A and B; vaccine will contain a cell surface part of the ion channel protein M2, which...
BioCentury | Aug 29, 2005
Strategy

Biovitrum's pipeline

Biovitrum's pipeline Biovitrum's pipeline After lead compounds BVT.933 and BVT.3498 (AMG 331) failed in the clinic in 2003 and 2004, Biovitrum set out to fill its pipeline via acquisitions, and early this year set itself...
Items per page:
1 - 3 of 3